LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Inicio・Lista de Acciones・Prothena Corp PLC

Prothena Corp PLC

Abierto

Sector Salud

21.95 -0.86

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

21.63

Máximo

22.42

Métricas clave
By Trading Economics
Ingresos	-72M
Ventas	-266K 50K
BPA	-1.34
Margen de beneficio	-144,478
EBITDA	-81M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+214.34 upside

Dividendos
By Dow Jones
Próximas Ganancias	31 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	38M 1.2B
Apertura anterior	22.81
Cierre anterior	21.95

Noticias sobre sentimiento de mercado

By Acuity

41%

59%

85 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

20.74 / 22.83 Soporte y Resistencia

Prothena Corp PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 may 2024, 22:51 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

Comparación entre iguales

Cambio de precio

Prothena Corp PLC Esperado

Precio Objetivo

By TipRanks

214.34% repunte

Estimación a 12 meses

Media 69.5 USD 214.34%

Máximo 94 USD

Mínimo 24 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Prothena Corp PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Prothena Corp PLC Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

20.74 / 22.83Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bearish event.

Sentimiento

By Acuity

85 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

EBITDA

Beneficio operativo

Acerca de Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.